REVIEWS

The British Journal of Pharmacology has an established commitment to publishing reviews. We recruit short (4,000-8,000 words) articles, and publish them with a quick turnaround. Authors of review articles are advised to read the Reviews Guidelines before submitting their reviews for publication in the British Journal of Pharmacology. In order to ensure good coverage, we have recruited a group of editors with a range of specialisations, each of whom has the mandate to recruit 3 or more articles each year in their areas. We are also open to suggestions and proposals for articles from our readership. Correspondence in this regard should be sent by email to michael.curtis@kcl.ac.uk. Now that we have moved on from the eras of prostaglandins and nitric oxide, it will be intriguing to follow the fortunes of the field as expressed in the pages of the journal. For example, will endocannabinoids become the new nitric oxide, or will biomarkers, drug safety and model validation become the new hot topics? Our review articles are intended to inform the process. Pharmacology is about drugs and the hunt for drugs. This is an opportunity for Industry and Academia to test the progress of their chosen interests by academic review. We look forward to your participation.

Access to selected reviews is FREE. Use the below links to browse review articles by year of publication:

2008 |
2007 |
2006 |
2005 |
2004 |
2003 |
2002 |
2001 |
2000 |
1999 |
1998 |

Top of page

2008

The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor
P Holzer
British Journal of Pharmacology 155, 1145-1162

On contemporaneous controls, unlikely outcomes, boxes and replacing the 'Student': Good statistical practice in pharmacology, problem 3
M J Lew
British Journal of Pharmacology 155, 797-803

Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders
P J Syapin
British Journal of Pharmacology 155, 623-640

COPD: what is the unmet need?
P M A Calverley
British Journal of Pharmacology 155, 487-493

Adenosine receptors and asthma in humans
C N Wilson
British Journal of Pharmacology 155, 475-486

Treating lung inflammation with agonists of the adenosine A_2A receptor: promises, problems and potential solutions
M A Trevethick, S J Mantell, E F Stuart, A Barnard, K N Wright and M Yeadon
British Journal of Pharmacology 155, 463-474

Pulmonary hypertension: therapeutic targets within the serotonin system
Y Dempsie and M R MacLean
British Journal of Pharmacology 155, 455-462

Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension
M Oka, K A Fagan, P L Jones and I F McMurtry
British Journal of Pharmacology 155, 444-454

Human embryonic stem cells and lung regeneration
A Varanou, C P Page and S L Minger
British Journal of Pharmacology 155, 316-325

PDE4 inhibitors: current status
D Spina
British Journal of Pharmacology 155, 308-315

Mechanisms of oxygen sensing: a key to therapy of pulmonary hypertension and patent ductus arteriosus
E K Weir, M Obreztchikova, A Vargese, J A Cabrera, D A Peterson and Z Hong
British Journal of Pharmacology 155, 300-307

Novel long-acting bronchodilators for COPD and asthma
M Cazzola and M G Matera
British Journal of Pharmacology 155, 291-299

The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles
B Mayer and M Beretta
British Journal of Pharmacology 155, 170-184

Annexin-A1: a pivotal regulator of the innate and adaptive immune systems
F D'Acquisto, M Perretti and R J Flower
British Journal of Pharmacology 155, 152-169

On the fitting of binding data when receptor dimerization is suspected
J Giraldo
British Journal of Pharmacology 155, 17-23

Arachidonic acid and ion channels: an update
H Meves
British Journal of Pharmacology 155, 4-16

Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK
A R Green
British Journal of Pharmacology 154, 1583-1599

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders
B M Jensen, C Akin and A M Gilfillan
British Journal of Pharmacology 154, 1572-1582

Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans
I Wessler and C J Kirkpatrick
British Journal of Pharmacology 154, 1558-1571

Moving towards better predictors of drug-induced torsades de pointes
A S Bass, B Darpo, J-P Valentin, P Sager and K Thomas
British Journal of Pharmacology 154, 1550-1553

Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes
P T Sager
British Journal of Pharmacology 154, 1544-1549

Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective
C E Pollard, J-P Valentin and T G Hammond
British Journal of Pharmacology 154, 1538-1543

Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
A Sugiyama
British Journal of Pharmacology 154, 1528-1537

Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability
M A Vos
British Journal of Pharmacology 154, 1523-1527

In vitro models of proarrhythmia
C L Lawrence, C E Pollard, T G Hammond and J-P Valentin
British Journal of Pharmacology 154, 1516-1522

The impact of varying autonomic states on the dynamic beat-to-beat QT–RR and QT–TQ interval relationships
A A Fossa
British Journal of Pharmacology 154, 1508-1515

Cellular basis of drug-induced torsades de pointes
D M Roden
British Journal of Pharmacology 154, 1502-1507

Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery
T P Barros, W K Alderton, H M Reynolds, A G Roach and S Berghmans
British Journal of Pharmacology 154, 1400-1413

Principles of Safety Pharmacology
M K Pugsley, S Authier and M J Curtis
British Journal of Pharmacology 154, 1382-1399

Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?
R Jockers, P Maurice, J A Boutin and P Delagrange
British Journal of Pharmacology 154, 1182-1195

The histamine H₃ receptor: an attractive target for the treatment of cognitive disorders
T A Esbenshade, K E Browman, R S Bitner, M Strakhova, M D Cowart and J D Brioni
British Journal of Pharmacology 154, 1166-1181

Future innovations in anti-platelet therapies
N E Barrett, L Holbrook, S Jones, W J Kaiser, L A Moraes, R Rana, T Sage, R G Stanley, K L Tucker, B Wright and J M Gibbins
British Journal of Pharmacology 154, 918-939

DNAzymes and cardiovascular disease
V L Benson, L M Khachigian and H C Lowe
British Journal of Pharmacology 154, 741-748

Negative regulation of multifunctional Ca²⁺/calmodulin-dependent protein kinases: physiological and pharmacological significance of protein phosphatases
A Ishida, N Sueyoshi, Y Shigeri and I Kameshita
British Journal of Pharmacology 154, 729-740

Gene doping: the hype and the reality
D J Wells
British Journal of Pharmacology 154, 623-631

Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
J R Docherty
British Journal of Pharmacology 154, 606-622

Indirect androgen doping by oestrogen blockade in sports
D J Handelsman
British Journal of Pharmacology 154, 598-605

The rush to adrenaline: drugs in sport acting on the -adrenergic system
E Davis, R Loiacono and R J Summers
British Journal of Pharmacology 154, 584-597

Gonadotropins in doping: pharmacological basis and detection of illicit use
U-H Stenman, K Hotakainen and H Alfthan
British Journal of Pharmacology 154, 569-583

Regulation of muscle mass by growth hormone and IGF-I
C P Velloso
British Journal of Pharmacology 154, 557-568

Growth hormone, IGF-I and insulin and their abuse in sport
R I G Holt and P H Sönksen
British Journal of Pharmacology 154, 542-556

Erythropoiesis-stimulating agents and other methods to enhance oxygen transport
S Elliott
British Journal of Pharmacology 154, 529-541

Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement
F Kadi
British Journal of Pharmacology 154, 522-528

Pharmacology of anabolic steroids
A T Kicman
British Journal of Pharmacology 154, 502-521

Drugs in sport: a scientist–athlete's perspective: from ambition to neurochemistry
M Spedding and C Spedding
British Journal of Pharmacology 154, 496-501

Addiction: the clinical interface
D Nutt and A Lingford-Hughes
British Journal of Pharmacology 154, 397-405

Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction
M J Christie
British Journal of Pharmacology 154, 384-396

The endocannabinoid system in brain reward processes
M Solinas, S R Goldberg and D Piomelli
British Journal of Pharmacology 154, 369-383

From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?
I S McGregor, P D Callaghan and G E Hunt
British Journal of Pharmacology 154, 358-368

A neuropeptide-centric view of psychostimulant addiction
B Boutrel
British Journal of Pharmacology 154, 343-357

Neuroplasticity in the mesolimbic dopamine system and cocaine addiction
M J Thomas, P W Kalivas and Y Shaham
British Journal of Pharmacology 154, 327-342

Inhalant abuse among adolescents: neurobiological considerations
D I Lubman, M Yücel and A J Lawrence
British Journal of Pharmacology 154, 316-326

Neuropharmacology of alcohol addiction
V Vengeliene, A Bilbao, A Molander and R Spanagel
British Journal of Pharmacology 154, 299-315

Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABA_A receptors as an opportunity for drug development?
M Wallner and R W Olsen
British Journal of Pharmacology 154, 288-298

Genetic factors influencing alcohol dependence
R D Mayfield, R A Harris and M A Schuckit
British Journal of Pharmacology 154, 275-287

The neurocircuitry of addiction: an overview
M W Feltenstein and R E See
British Journal of Pharmacology 154, 261-274

Asthma from a pharmacogenomic point of view
C Szalai, I Ungvári, L Pelyhe, G Tölgyesi and A Falus
British Journal of Pharmacology 153, 1602-1614

Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents
G Heusch
British Journal of Pharmacology 153, 1589-1601

Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors
P G Strange
British Journal of Pharmacology 153, 1353-1363

Tumour endoproteases: the cutting edge of cancer drug delivery?
J M Atkinson, C S Siller and J H Gill
British Journal of Pharmacology 153, 1344-1352

The cardiac persistent sodium current: an appealing therapeutic target?
D A Saint
British Journal of Pharmacology 153, 1133-1142

Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
J C Shryock and L Belardinelli
British Journal of Pharmacology 153, 1128-1132

Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children
U Nowak-Göttl, C Bidlingmaier, A Krümpel, L Göttl and G Kenet
British Journal of Pharmacology 153, 1120-1127

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
N S Kirkby, P W F Hadoke, A J Bagnall and D J Webb
British Journal of Pharmacology 153, 1105-1119

A Holy Grail of asthma management: toward understanding how long-acting ₂-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids
M A Giembycz, M Kaur, R Leigh and R Newton
British Journal of Pharmacology 153, 1090-1104

Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders
R Farré and D Sifrim
British Journal of Pharmacology 153, 858-869

Store-operated calcium entry in vascular smooth muscle
F P Leung, L M Yung, X Yao, I Laher and Y Huang
British Journal of Pharmacology 153, 846-857

Biomarker method validation in anticancer drug development
J Cummings, T H Ward, A Greystoke, M Ranson and C Dive
British Journal of Pharmacology 153, 646-656

Thiazolidinediones: effects on insulin resistance and the cardiovascular system
C E Quinn, P K Hamilton, C J Lockhart and G E McVeigh
British Journal of Pharmacology 153, 636-645

Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis
S P Gieseg, E M Crone, E A Flavall and Z Amit
British Journal of Pharmacology 153, 627-635

Pharmacological Onomastics: What's in a name?
T P Kenakin
British Journal of Pharmacology 153, 432-438

Neuropeptide Y Y2 receptor in health and disease
S L Parker and A Balasubramaniam
British Journal of Pharmacology 153, 420-431

Prostamides (prostaglandin-ethanolamides) and their pharmacology
D F Woodward, Y Liang and A H-P Krauss
British Journal of Pharmacology 153, 410-419

Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands
A Poso and J W Huffman
British Journal of Pharmacology 153, 335-346

Cannabinoid CB₂ receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
J Guindon and A G Hohmann
British Journal of Pharmacology 153, 319-334

The peripheral cannabinoid receptor knockout mice: an update
N E Buckley
British Journal of Pharmacology 153, 309-318

CB₂ receptor-mediated migration of immune cells: it can go either way
A M Miller and N Stella
British Journal of Pharmacology 153, 299-308

Cannabinoid receptors in acute and chronic complications of atherosclerosis
F Mach, F Montecucco and S Steffens
British Journal of Pharmacology 153, 290-298

CB2 receptors as new therapeutic targets for liver diseases
S Lotersztajn, F Teixeira-Clerc, B Julien, V Deveaux, Y Ichigotani, S Manin, J Tran-Van-Nhieu, M Karsak, A Zimmer and A Mallat
British Journal of Pharmacology 153, 286-289

Cannabinoid CB₂ receptors in human brain inflammation
C Benito, R M Tol|[oacute]|n, M R Pazos, E N|[uacute]||[ntilde]|ez, A I Castillo and J Romero
British Journal of Pharmacology 153, 277-285

Direct suppression of autoreactive lymphocytes in the central nervous system via the CB₂ receptor
B N Dittel
British Journal of Pharmacology 153, 271-276

Cannabinoid CB₂ receptors in the gastrointestinal tract: a regulatory system in states of inflammation
K L Wright, M Duncan and K A Sharkey
British Journal of Pharmacology 153, 263-270

Endocannabinoids and cannabinoid receptors in ischaemia|[ndash]|reperfusion injury and preconditioning
P Pacher and G Hask|[oacute]|
British Journal of Pharmacology 153, 252-262

CB₂ receptors in the brain: role in central immune function
G A Cabral, E S Raborn, L Griffin, J Dennis and F Marciano-Cabral
British Journal of Pharmacology 153, 240-251

Biology and therapeutic potential of cannabinoid CB₂ receptor inverse agonists
C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell and L Bober
British Journal of Pharmacology 153, 226-239

CB₂ cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
|[Aacute]| Ar|[eacute]|valo-Mart|[iacute]|n, D Garc|[iacute]|a-Ovejero, O G|[oacute]|mez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado and F Molina-Holgado
British Journal of Pharmacology 153, 216-225

The diverse CB₁ and CB₂ receptor pharmacology of three plant cannabinoids: |[Delta]|⁹-tetrahydrocannabinol, cannabidiol and |[Delta]|⁹-tetrahydrocannabivarin
R G Pertwee
British Journal of Pharmacology 153, 199-215

CB₂ receptors in reproduction
M Maccarrone
British Journal of Pharmacology 153, 189-198

Cannabinoid receptors and the regulation of bone mass
I Bab and A Zimmer
British Journal of Pharmacology 153, 182-188

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment  
J A Pratt, C Winchester, A Egerton, S M Cochran and B J Morris
British Journal of Pharmacology 153, S465-S470

Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells  
M Sitkovsky, D Lukashev, S Deaglio, K Dwyer, S C Robson and A Ohta
British Journal of Pharmacology 153, S457-S464

Adenosine receptors and asthma  
R A Brown, D Spina and C P Page
British Journal of Pharmacology 153, S446-S456

The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology  
U Maskos
British Journal of Pharmacology 153, S438-S445

The role of GSK-3 in synaptic plasticity  
S Peineau, C Bradley, C Taghibiglou, A Doherty, Z A Bortolotto, Y T Wang and G L Collingridge
British Journal of Pharmacology 153, S428-S437

Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects  
P Fischer and D Hilfiker-Kleiner
British Journal of Pharmacology 153, S414-S427

Molecular epidemiology of clinically significant antibiotic resistance genes  
P M Hawkey
British Journal of Pharmacology 153, S406-S413

Experimental models, neurovascular mechanisms and translational issues in stroke research  
E H Lo
British Journal of Pharmacology 153, S396-S405

Probing the role of AMPAR endocytosis and long-term depression in behavioural sensitization: relevance to treatment of brain disorders, including drug addiction  
Y T Wang
British Journal of Pharmacology 153, S389-S395

Agonist-selective mechanisms of GPCR desensitization  
E Kelly, C P Bailey and G Henderson
British Journal of Pharmacology 153, S379-S388

Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?  
R C Chambers
British Journal of Pharmacology 153, S367-S378

Conformational changes in G-protein-coupled receptors—the quest for functionally selective conformations is open  
C Hoffmann, A Zürn, M Bünemann and M J Lohse
British Journal of Pharmacology 153, S358-S366

Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria  
P M Bennett
British Journal of Pharmacology 153, S347-S357

Orphan GPCR research  
S Chung, T Funakoshi and O Civelli
British Journal of Pharmacology 153, S339-S346

Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly  
A R Green
British Journal of Pharmacology 153, S325-S338

Role of the brain-derived neurotrophic factor at glutamatergic synapses  
A L Carvalho, M V Caldeira, S D Santos and C B Duarte
British Journal of Pharmacology 153, S310-S324

-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction  
K DeFea
British Journal of Pharmacology 153, S298-S309

Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission  
R Exley and S J Cragg
British Journal of Pharmacology 153, S283-S297

Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more  
R Ramachandran and M D Hollenberg
British Journal of Pharmacology 153, S263-S282

Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems  
D Bell and B J McDermott
British Journal of Pharmacology 153, S247-S262

Fibroblasts as novel therapeutic targets in chronic inflammation  
S J Flavell, T Z Hou, S Lax, A D Filer, M Salmon and C D Buckley
British Journal of Pharmacology 153, S241-S246

Gastrointestinal roles for proteinase-activated receptors in health and disease  
A Kawabata, M Matsunami and F Sekiguchi
British Journal of Pharmacology 153, S230-S240

A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization  
G Milligan
British Journal of Pharmacology 153, S216-S229

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus  
C N Serhan and N Chiang
British Journal of Pharmacology 153, S200-S215

The roles of the prostaglandin D₂ receptors DP₁ and CRTH2 in promoting allergic responses  
R Pettipher
British Journal of Pharmacology 153, S191-S199

The A_2A-adenosine receptor: a GPCR with unique features?  
J Zezula and M Freissmuth
British Journal of Pharmacology 153, S184-S190

RIC-3: a nicotinic acetylcholine receptor chaperone  
N S Millar
British Journal of Pharmacology 153, S177-S183

G-protein-coupled receptor phosphorylation: where, when and by whom  
A B Tobin
British Journal of Pharmacology 153, S167-S176

Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors  
M M Rosenkilde, M J Smit and M Waldhoer
British Journal of Pharmacology 153, S154-S166

Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis  
P H Sugden, S J Fuller, S C Weiss and A Clerk
British Journal of Pharmacology 153, S137-S153

The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders  
E Schwarz and S Bahn
British Journal of Pharmacology 153, S133-S136

Kinetics of G-protein-coupled receptor signals in intact cells  
M J Lohse, P Hein, C Hoffmann, V O Nikolaev, J-P Vilardaga and M Bünemann
British Journal of Pharmacology 153, S125-S132

Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential  
S M Lawrie, J Hall, A M McIntosh, D G Cunningham-Owens and E C Johnstone
British Journal of Pharmacology 153, S120-S124

Clinical pharmacological issues in the development of acute stroke therapies  
G A Ford
British Journal of Pharmacology 153, S112-S119

Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications  
E D Burg, C V Remillard and J X-J Yuan
British Journal of Pharmacology 153, S99-S111

G-protein-coupled receptor heteromers: function and ligand pharmacology  
R Franco, V Casadó, A Cortés, J Mallol, F Ciruela, S Ferré, C Lluis and E I Canela
British Journal of Pharmacology 153, S90-S98

Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions  
J-D Maréchal, C A Kemp, G C K Roberts, M J I Paine, C R Wolf and M J Sutcliffe
British Journal of Pharmacology 153, S82-S89

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity  
H A Overton, M C T Fyfe and C Reynet
British Journal of Pharmacology 153, S76-S81

Nicotinic acid: an old drug with a promising future  
E T Bodor and S Offermanns
British Journal of Pharmacology 153, S68-S75

Ligand discovery and virtual screening using the program LIDAEUS  
P Taylor, E Blackburn, Y G Sheng, S Harding, K-Y Hsin, D Kan, S Shave and M D Walkinshaw
British Journal of Pharmacology 153, S55-S67

Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery  
R R Moustafa and J-C Baron
British Journal of Pharmacology 153, S44-S54

Intracellular machinery for the transport of AMPA receptors  
J A Esteban
British Journal of Pharmacology 153, S35-S43

Suppression of inflammatory and immune responses by the A_2A adenosine receptor: an introduction  
T M Palmer and M A Trevethick
British Journal of Pharmacology 153, S27-S34

Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go  
N Moitessier, P Englebienne, D Lee, J Lawandi and C R Corbeil
British Journal of Pharmacology 153, S7-S26

Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics
M-S Suleiman, K Zacharowski and G D Angelini
British Journal of Pharmacology 153, 21-33

Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors
A Negre-Salvayre, C Coatrieux, C Ingueneau and R Salvayre
British Journal of Pharmacology 153, 6-20

Top of page

2007

Human African trypanosomiasis: pharmacological re-engagement with a neglected disease
M P Barrett, D W Boykin, R Brun and R R Tidwell
British Journal of Pharmacology 152, 1155-1171

Novel approaches to developing new antibiotics for bacterial infections
A R M Coates and Y Hu
British Journal of Pharmacology 152, 1147-1154

Telomerase and its potential for therapeutic intervention
P Phatak and A M Burger
British Journal of Pharmacology 152, 1003-1011

Novel uses for anti-platelet agents as anti-inflammatory drugs
S C Pitchford
British Journal of Pharmacology 152, 987-1002

Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling
D S Burley, P Ferdinandy and G F Baxter
British Journal of Pharmacology 152, 855-869

Myeloperoxidase: a target for new drug development?
E Malle, P G Furtmüller, W Sattler and C Obinger
British Journal of Pharmacology 152, 838-854

Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β-cells
I Matias, M-P Gonthier, S Petrosino, L Docimo, R Capasso, L Hoareau, P Monteleone, R Roche, A A Izzo and V Di Marzo
British Journal of Pharmacology 152, 676-690

Endocannabinoids and the haematological system
M D Randall
British Journal of Pharmacology 152, 671-675

Endocannabinoids and the gastrointestinal tract: what are the key questions?
G J Sanger
British Journal of Pharmacology 152, 663-670

Alzheimer's disease; taking the edge off with cannabinoids?
V A Campbell and A Gowran
British Journal of Pharmacology 152, 655-662

Cannabinoid control of neuroinflammation related to multiple sclerosis
D Baker, S J Jackson and G Pryce
British Journal of Pharmacology 152, 649-654

Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate
K Rea, M Roche and D P Finn
British Journal of Pharmacology 152, 633-648

Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
M D Jhaveri, D Richardson and V Chapman
British Journal of Pharmacology 152, 624-632

The complications of promiscuity: endocannabinoid action and metabolism
S P H Alexander and D A Kendall
British Journal of Pharmacology 152, 602-623

The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action
C J Fowler
British Journal of Pharmacology 152, 594-601

Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences
J M McPartland, M Glass and R G Pertwee
British Journal of Pharmacology 152, 583-593

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors
S E O'Sullivan
British Journal of Pharmacology 152, 576-582

Novel cannabinoid receptors
A J Brown
British Journal of Pharmacology 152, 567-575

Function, structure and therapeutic potential of complement C5a receptors
P N Monk, A-M Scola, P Madala and D P Fairlie
British Journal of Pharmacology 152, 429-448

Building a better aspirin: gaseous solutions to a century-old problem
J L Wallace
British Journal of Pharmacology 152, 421-428

Good statistical practice in pharmacology Problem 2
M Lew
British Journal of Pharmacology 152, 299-303

Good statistical practice in pharmacology Problem 1
M Lew
British Journal of Pharmacology 152, 295-298

Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature
A K Chow, J Cena and R Schulz
British Journal of Pharmacology 152, 189-205

Cardiovascular gene therapy: current status and therapeutic potential
M M Gaffney, S O Hynes, F Barry and T O'Brien
British Journal of Pharmacology 152, 175-188

The potential of high-content high-throughput microscopy in drug discovery
V Starkuviene and R Pepperkok
British Journal of Pharmacology 152, 62-71

Origin and evolution of high throughput screening
D A Pereira and J A Williams
British Journal of Pharmacology 152, 53-61

Chemogenomic approaches to rational drug design
D Rognan
British Journal of Pharmacology 152, 38-52

In silico pharmacology for drug discovery: applications to targets and beyond
S Ekins, J Mestres and B Testa
British Journal of Pharmacology 152, 21-37

In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
S Ekins, J Mestres and B Testa
British Journal of Pharmacology 152, 9-20

Mitochondrial Medicine: Pharmacological targeting of mitochondria in disease
J S Armstrong
British Journal of Pharmacology 151, 1154-1165

Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
E J Mead, J J Maguire, R E Kuc and A P Davenport
British Journal of Pharmacology 151, 1143-1153

Nitric oxide homeostasis as a target for drug additives to cardioplegia
B K Podesser and S Hallström
British Journal of Pharmacology 151, 930-940

The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
W J de Jonge and L Ulloa
British Journal of Pharmacology 151, 915-929

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
P K Gillman
British Journal of Pharmacology 151, 737-748

Chemokines and their receptors as potential targets for the treatment of asthma
C Palmqvist, A J Wardlaw and P Bradding
British Journal of Pharmacology 151, 725-736

Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties
K Oettl and R E Stauber
British Journal of Pharmacology 151, 580-590

Discovery of P2X₇ receptor-selective antagonists offers new insights into P2X₇ receptor function and indicates a role in chronic pain states
D L Donnelly-Roberts and M F Jarvis
British Journal of Pharmacology 151, 571-579

Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions
V E Mendizábal and E Adler-Graschinsky
British Journal of Pharmacology 151, 427-440

Recent developments in nitric oxide donor drugs
M R Miller and I L Megson
British Journal of Pharmacology 151, 305-321

The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)
L J A Hardwick, S Velamakanni and H W van Veen
British Journal of Pharmacology 151, 163-174

Heparanase: a target for drug discovery in cancer and inflammation
E A McKenzie
British Journal of Pharmacology 151, 1-14

Inflammation as a causative factor in the aetiology of Parkinson's disease
P S Whitton
British Journal of Pharmacology 150, 963-976

PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?
M M Mocanu and D M Yellon
British Journal of Pharmacology 150, 833-838

Relaxin Family Peptide Receptors – former orphans reunite with their parent ligands to activate multiple signalling pathways
M L Halls, E T van der Westhuizen, R A D Bathgate and R J Summers
British Journal of Pharmacology 150, 677-691

Nanoparticles: pharmacological and toxicological significance
C Medina, M J Santos-Martinez, A Radomski, O I Corrigan and M W Radomski
British Journal of Pharmacology 150, 552-558

Taking The Time To Study Competitive Antagonism
D J A Wyllie and P E Chen
British Journal of Pharmacology 150, 541-551

Cellular mechanisms underlying the pharmacological induction of phosphenes
L Cervetto, G C Demontis and C Gargini
British Journal of Pharmacology 150, 383-390

Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement
P M Beart and R D O'Shea
British Journal of Pharmacology 150, 5-17

Top of page

2006

Trace amine-associated receptors and their ligands
R Zucchi, G Chiellini, T S Scanlan and D K Grandy
British Journal of Pharmacology 149, 967-978

The MC4 receptor and control of appetite
R A H Adan, B Tiesjema, J J G Hillebrand, S E la Fleur, M J H Kas and M de Krom
British Journal of Pharmacology 149, 815-827

Prostaglandin E₂ receptor distribution and function in the gastrointestinal tract
I Dey, M Lejeune and K Chadee
British Journal of Pharmacology 149, 611-623

Cholinergic regulation of epithelial ion transport in the mammalian intestine
C L Hirota and D M McKay
British Journal of Pharmacology 149, 463-479

Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
Gurminder Singh and Anthony P Davenport
British Journal of Pharmacology 148, 1033-1041

The role of urotensin II in cardiovascular and renal physiology and diseases
Yi-Chun Zhu, Yi-Zhun Zhu and Philip Keith Moore
British Journal of Pharmacology 148, 884-901

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Paul Abrams, Karl-Erik Andersson, Jerry J Buccafusco, Christopher Chapple, William Chet de Groat, Alison D Fryer, Gary Kay, Alan Laties, Neil M Nathanson, Pankaj Jay Pasricha and Alan J Wein
British Journal of Pharmacology 148, 565-578

How corticosteroids control inflammation
Peter J Barnes
British Journal of Pharmacology 148, 245-254

Cannabinoids and cancer: pros and cons of an antitumour strategy
Maurizio Bifulco, Chiara Laezza, Simona Pisanti and Patrizia Gazzerro
British Journal of Pharmacology 148, 123-135

Pharmacological insights obtained from structure–function studies of ionotropic glutamate receptors
Philip E Chen and David J A Wyllie
British Journal of Pharmacology 147, 839-853

Mitochondria: a target for cancer therapy
Jeffrey S Armstrong
British Journal of Pharmacology 147, 239-248

Late-stage clinical development in lower urogenital targets: sexual dysfunction
Usman Azam
British Journal of Pharmacology 147, S153-S159

Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting
Arich Ryan Reynolds and Natasha Kyprianou
British Journal of Pharmacology 147, S144-S152

Purinoceptors as therapeutic targets for lower urinary tract dysfunction
Anthony P D W Ford, Joel R Gever, Philip A Nunn, Yu Zhong, Joseph S Cefalu, Michael P Dillon and Debra A Cockayne
British Journal of Pharmacology 147, S132-S143

The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition
Andrew G Ramage
British Journal of Pharmacology 147, S120-S131

α₁-, α₂- and β-adrenoceptors in the urinary bladder, urethra and prostate
Martin C Michel and Wim Vrydag
British Journal of Pharmacology 147, S88-S119

Muscarinic receptors in the bladder: from basic research to therapeutics
Sharath S Hegde
British Journal of Pharmacology 147, S80-S87

Animal models in urological disease and sexual dysfunction
Gordon McMurray, James H Casey and Alasdair M Naylor
British Journal of Pharmacology 147, S62-S79

In vitro models: research in physiology and pharmacology of the lower urinary tract
Robert B Moreland
British Journal of Pharmacology 147, S56-S61

Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction
George J Christ and Steve Hodges
British Journal of Pharmacology 147, S41-S55

Integrative control of the lower urinary tract: preclinical perspective
William C de Groat
British Journal of Pharmacology 147, S25-S40

Integrated control of lower urinary tract – clinical perspective
Clare J Fowler
British Journal of Pharmacology 147, S14-S24

Lower urinary tract disease: what are we trying to treat and in whom?
Jeremy P W Heaton
British Journal of Pharmacology 147, S2-S13

The future of pharmacology
Patrick Vallance and Trevor G Smart
British Journal of Pharmacology 147, S304-S307

Drugs for asthma
Peter J Barnes
British Journal of Pharmacology 147, S297-S303

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
Moussa B H Youdim and Y S Bakhle
British Journal of Pharmacology 147, S287-S296

Neuromuscular block
W C Bowman
British Journal of Pharmacology 147, S277-S286

Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
V Craig Jordan
British Journal of Pharmacology 147, S269-S276

Glucocorticoids: exemplars of multi-tasking
Julia C Buckingham
British Journal of Pharmacology 147, S258-S268

Phosphodiesterase inhibitors
Victoria Boswell-Smith, Domenico Spina and Clive P Page
British Journal of Pharmacology 147, S252-S257

Antiplatelet drugs
Gustav Born and Carlo Patrono
British Journal of Pharmacology 147, S241-S251

The role of inflammation in CNS injury and disease
Sian-Marie Lucas, Nancy J Rothwell and Rosemary M Gibson
British Journal of Pharmacology 147, S232-S240

Antiarrhythmic drug research
M J A Walker
British Journal of Pharmacology 147, S222-S231

The attraction of chemokines as a target for specific anti-inflammatory therapy
James E Pease and Timothy J Williams
British Journal of Pharmacology 147, S212-S221

Neuropeptides and their receptors: innovative science providing novel therapeutic targets
Susan D Brain and Helen M Cox
British Journal of Pharmacology 147, S202-S211

The discovery of nitric oxide and its role in vascular biology
S Moncada and E A Higgs
British Journal of Pharmacology 147, S193-S201

Prostaglandins, bioassay and inflammation
R J Flower
British Journal of Pharmacology 147, S182-S192

Purinergic signalling
Geoffrey Burnstock
British Journal of Pharmacology 147, S172-S181

Cannabinoid pharmacology: the first 66 years
Roger G Pertwee
British Journal of Pharmacology 147, S163-S171

75 years of opioid research: the exciting but vain quest for the Holy Grail
Alistair D Corbett, Graeme Henderson, Alexander T McKnight and Stewart J Paterson
British Journal of Pharmacology 147, S153-S162

Neuropharmacology of 5-hydroxytryptamine
A Richard Green
British Journal of Pharmacology 147, S145-S152

Dopamine: the rewarding years
Charles A Marsden
British Journal of Pharmacology 147, S136-S144

Histamine and its receptors
Mike E Parsons and C Robin Ganellin
British Journal of Pharmacology 147, S127-S135

Acetylcholine
David A Brown
British Journal of Pharmacology 147, S120-S126

GABA and glycine as neurotransmitters: a brief history
N G Bowery and T G Smart
British Journal of Pharmacology 147, S109-S119

The glutamate story
Jeffrey C Watkins and David E Jane
British Journal of Pharmacology 147, S100-S108

Drug metabolism and pharmacogenetics: the British contribution to fields of international significance
John Caldwell
British Journal of Pharmacology 147, S89-S99

Neurotransmitter transporters and their impact on the development of psychopharmacology
Leslie Iversen
British Journal of Pharmacology 147, S82-S88

Molecular targets underlying general anaesthesia
Nicholas P Franks
British Journal of Pharmacology 147, S72-S81

Potassium channels – multiplicity and challenges
Donald H Jenkinson
British Journal of Pharmacology 147, S63-S71

A short history of voltage-gated calcium channels
Annette C Dolphin
British Journal of Pharmacology 147, S56-S62

Heterotrimeric G-proteins: a short history
Graeme Milligan and Evi Kostenis
British Journal of Pharmacology 147, S46-S55

Pharmacology of intracellular signalling pathways
Stefan R Nahorski
British Journal of Pharmacology 147, S38-S45

G-protein-coupled receptors: past, present and future
Stephen J Hill
British Journal of Pharmacology 147, S27-S37

Agonist-activated ion channels
David Colquhoun
British Journal of Pharmacology 147, S17-S26

The receptor concept: pharmacology's big idea
H P Rang
British Journal of Pharmacology 147, S9-S16

Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
Erik De Clercq and Hugh J Field
British Journal of Pharmacology 147, 1-11

Top of page

2005

The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Alessandra Gaeta and Robert C Hider
British Journal of Pharmacology 146, 1041-1059

Heat shock proteins as emerging therapeutic targets
Csaba Sõti, Enikõ Nagy, Zoltán Giricz, László Vígh, Péter Csermely and Péter Ferdinandy
British Journal of Pharmacology 146, 769-780

Dopaminergic neurones: much more than dopamine?
Vincent Seutin
British Journal of Pharmacology 146, 167-169

The identification of the adenosine A_2B receptor as a novel therapeutic target in asthma
Stephen T Holgate
British Journal of Pharmacology 145, 1009-1015

Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation
Hugh Clements-Jewery, David J Hearse and Michael J Curtis
British Journal of Pharmacology 145, 551-564

Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense
John L Wallace and Pallavi R Devchand
British Journal of Pharmacology 145, 275-282

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
Shannon M Bates and Jeffrey I Weitz
British Journal of Pharmacology 144, 1017-1028

Vasomotion: cellular background for the oscillator and for the synchronization of smooth muscle cells
Christian Aalkjær and Holger Nilsson
British Journal of Pharmacology 144, 605-616

The expanding field of cannabimimetic and related lipid mediators
Heather B Bradshaw and J Michael Walker
British Journal of Pharmacology 144, 459-465

Endothelium-dependent contractions in hypertension
Paul M Vanhoutte, Michel Feletou and Stefano Taddei
British Journal of Pharmacology 144, 449-458

Top of page

2004

Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation
Paul Jurasz, David Alonso-Escolano and Marek W Radomski
British Journal of Pharmacology 143, 819-826

Kinin B₁ receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes
João B Calixto, Rodrigo Medeiros, Elizabeth S Fernandes, Juliano Ferreira, Daniela A Cabrini and Maria M Campos
British Journal of Pharmacology 143, 803-818

-Opioid receptor desensitization: Is morphine different?
Mark Connor, Peregrine B Osborne and MacDonald J Christie
British Journal of Pharmacology 143, 685-696

Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites
Astrid E Alewijnse, Stephan L M Peters and Martin C Michel
British Journal of Pharmacology 143, 666-684

The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology
Rennolds S Ostrom and Paul A Insel
British Journal of Pharmacology 143, 235-245

Marijuana and cannabinoid regulation of brain reward circuits
Carl R Lupica, Arthur C Riegel and Alexander F Hoffman
British Journal of Pharmacology 143, 227-234

Efficacy in CB₁ receptor-mediated signal transduction
Allyn C Howlett
British Journal of Pharmacology 142, 1209-1218

Functional M₃ muscarinic acetylcholine receptors in mammalian hearts
Zhiguo Wang, Hong Shi and Huizhen Wang
British Journal of Pharmacology 142, 395-408

Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?
Barry Halliwell and Matthew Whiteman
British Journal of Pharmacology 142, 231-255

The complexities of the cardiovascular actions of cannabinoids
Michael D Randall, David A Kendall and Saoirse O'Sullivan
British Journal of Pharmacology 142, 20-26

Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE)
Marco A Diana and Alain Marty
British Journal of Pharmacology 142, 9-19

Involvement of cannabinoid receptors in gut motility and visceral perception
Pamela J Hornby and Stephen M Prouty
British Journal of Pharmacology 141, 1335-1345

Peripheral kappa-opioid agonists for visceral pain
Pierre J-M Rivière
British Journal of Pharmacology 141, 1331-1334

CRF₁ receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome
Y Taché, V Martinez, L Wang and M Million
British Journal of Pharmacology 141, 1321-1330

Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function
Pierangelo Geppetti and Marcello Trevisani
British Journal of Pharmacology 141, 1313-1320

Neurokinin NK₁ and NK₃ receptors as targets for drugs to treat gastrointestinal motility disorders and pain
Gareth J Sanger
British Journal of Pharmacology 141, 1303-1312

Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome
James J Galligan
British Journal of Pharmacology 141, 1294-1302

Role of serotonin in the pathophysiology of the irritable bowel syndrome
Michael D Crowell
British Journal of Pharmacology 141, 1285-1293

Involvement of endogenous CCK and CCK₁ receptors in colonic motor function
Gábor Varga, András Bálint, Beáta Burghardt and Massimo D'Amato
British Journal of Pharmacology 141, 1275-1284

Modulation of visceral pain and inflammation by protease-activated receptors
Nathalie Vergnolle
British Journal of Pharmacology 141, 1264-1274

Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome
Alessandro Lecci, Angela Capriati and Carlo Alberto Maggi
British Journal of Pharmacology 141, 1249-1263

Treating irritable bowel syndrome: overview, perspective and future therapies
Michael Camilleri
British Journal of Pharmacology 141, 1237-1248

Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis?
Tudor M Griffith
British Journal of Pharmacology 141, 881-903

Cannabinoids and neuroinflammation
Lisa Walter and Nephi Stella
British Journal of Pharmacology 141, 775-785

The endocannabinoid system: a general view and latest additions
Luciano De Petrocellis, Maria Grazia Cascio and Vincenzo Di Marzo
British Journal of Pharmacology 141, 765-774

Top of page

2003

Angiotensin AT₂ receptors: cardiovascular hope or hype?
Robert E Widdop, Emma S Jones, Ruth E Hannan and Tracey A Gaspari
British Journal of Pharmacology 140, 809-824

Cellular accumulation of anandamide: consensus and controversy
Cecilia J Hillard and Abbas Jarrahian
British Journal of Pharmacology 140, 802-808

Anandamide and vanilloid TRPV1 receptors
Ruth A Ross
British Journal of Pharmacology 140, 790-801

Emerging roles for endocannabinoids in long-term synaptic plasticity
Gregory L Gerdeman and David M Lovinger
British Journal of Pharmacology 140, 781-789

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)
Ronnier J Aviles, Brian H Annex and Robert J Lederman
British Journal of Pharmacology 140, 637-646

Designer blood vessels and therapeutic revascularization
Joseph D Berglund and Zorina S Galis
British Journal of Pharmacology 140, 627-636

Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis
Georges von Degenfeld, Andrea Banfi, Matthew L Springer and Helen M Blau
British Journal of Pharmacology 140, 620-626

Paracrine control of vascularization and neurogenesis by neurotrophins
Costanza Emanueli, Peter Schratzberger, Rudolf Kirchmair and Paolo Madeddu
British Journal of Pharmacology 140, 614-619

Emerging concept in angiogenesis: specification of arterial and venous endothelial cells
Thomas N Sato
British Journal of Pharmacology 140, 611-613

Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells
Mary E Gerritsen, James E Tomlinson, Constance Zlot, Michael Ziman and Stuart Hwang
British Journal of Pharmacology 140, 595-610

Fishing for novel angiogenic therapies
Kameha R Kidd and Brant M Weinstein
British Journal of Pharmacology 140, 585-594

Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH₂-terminal kinase signaling pathways in human hepatoma HepG2 cells
Yan-Nian Chen, Chi-Chih Cheng, Jung-Chou Chen, Wei Tsauer and Shih-Lan Hsu
British Journal of Pharmacology 140, 461-470

On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies
Carolina Muscoli, Salvatore Cuzzocrea, Dennis P Riley, Jay L Zweier, Christoph Thiemermann, Zhi-Qiang Wang and Daniela Salvemini
British Journal of Pharmacology 140, 445-460

Muscarinic regulation of cardiac ion channels
Robert D Harvey and Andriy E Belevych
British Journal of Pharmacology 139, 1074-1084

Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells
Silvia Di Angelantonio, Rashid Giniatullin, Valeria Costa, Elena Sokolova and Andrea Nistri
British Journal of Pharmacology 139, 1061-1073

Brain renin–angiotensin system dysfunction in hypertension: recent advances and perspectives
Shereeni J Veerasingham and Mohan K Raizada
British Journal of Pharmacology 139, 191-202

Gene therapy for cerebral vascular disease: update 2003
Kazunori Toyoda, Yi Chu and Donald D Heistad
British Journal of Pharmacology 139, 1-9

Phorbol esters and neurotransmitter release: more than just protein kinase C?
Eugene M Silinsky and Timothy J Searl
British Journal of Pharmacology 138, 1191-1201

The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?
Richard D Jones, Peter J Pugh, T Hugh Jones and Kevin S Channer
British Journal of Pharmacology 138, 733-744

Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning
Péter Ferdinandy and Richard Schulz
British Journal of Pharmacology 138, 532-543

Top of page

2002

Is urotensin-II the new endothelin?
Janet J Maguire and Anthony P Davenport
British Journal of Pharmacology 137, 579-588

Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs
J E Keeble and P K Moore
British Journal of Pharmacology 137, 295-310

NO as a signalling molecule in the nervous system
Juan V Esplugues
British Journal of Pharmacology 135, 1079-1095

TNF ligands and receptors – a matter of life and death
David J MacEwan
British Journal of Pharmacology 135, 855-875

Role of bradykinin in preconditioning and protection of the ischaemic myocardium
G F Baxter and Z Ebrahim
British Journal of Pharmacology 135, 843-854

P2 receptors: new potential players in atherosclerosis
Francesco Di Virgilio and Anna Solini
British Journal of Pharmacology 135, 831-842

Protease activated receptor 2 and the cardiovascular system
Carla Cicala
British Journal of Pharmacology 135, 14-20

The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle
Ian McFadzean and Alan Gibson
British Journal of Pharmacology 135, 1-13

Top of page

2001

COX-2 and cancer: a new approach to an old problem
Y S Bakhle
British Journal of Pharmacology 134, 1137-1150

Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets
Thomas L Clemens, Sarah Cormier, Anne Eichinger, Karlhans Endlich, Nathalie Fiaschi-Taesch, Evelyne Fischer, Peter A Friedman, Andrew C Karaplis, Thierry Massfelder, Jérôme Rossert, Klaus-Dieter Schlüter, Caroline Silve, Andrew F Stewart, Karen Takane and Jean-Jacques Helwig
British Journal of Pharmacology 134, 1113-1136

Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions
Costanza Emanueli and Paolo Madeddu
British Journal of Pharmacology 133, 951-958

Biological significance of agmatine, an endogenous ligand at imidazoline binding sites
Walter Raasch, Ulrich Schäfer, Julian Chun and Peter Dominiak
British Journal of Pharmacology 133, 755-780

Top of page

2000

5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension
Margaret R MacLean, Philippe Herve, Saadia Eddahibi and Serge Adnot
British Journal of Pharmacology 131, 161-168

Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis
Benjamin L J Webb, Stuart J Hirst and Mark A Giembycz
British Journal of Pharmacology 130, 1433-1452

Endothelial dysfunction in diabetes
An S De Vriese, Tony J Verbeuren, Johan Van de Voorde, Norbert H Lameire and Paul M Vanhoutte
British Journal of Pharmacology 130, 963-974

Apoptosis in the vasculature: mechanisms and functional importance
Ziad Mallat and Alain Tedgui
British Journal of Pharmacology 130, 947-962

The muscarinic M₅ receptor: a silent or emerging subtype?
R M Eglen and S R Nahorski
British Journal of Pharmacology 130, 13-21

Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery
Rianne A F de Ligt, Angeliki P Kourounakis and Ad P IJzerman
British Journal of Pharmacology 130, 1-12

Pharmacology of nociceptin and its receptor: a novel therapeutic target
Girolamo Calo', Remo Guerrini, Anna Rizzi, Severo Salvadori and Domenico Regoli